BidaskClub upgraded shares of Cara Therapeutics (NASDAQ:CARA) from a hold rating to a buy rating in a research note released on Saturday morning, BidAskClub reports.

Several other analysts have also commented on CARA. Zacks Investment Research upgraded shares of Cara Therapeutics from a sell rating to a hold rating in a research report on Tuesday, January 14th. Needham & Company LLC reiterated a buy rating and issued a $35.00 price target on shares of Cara Therapeutics in a research report on Tuesday, December 3rd. Cantor Fitzgerald increased their price target on shares of Cara Therapeutics from $29.00 to $33.00 in a research report on Wednesday, December 4th. HC Wainwright reiterated a buy rating and issued a $30.00 price target on shares of Cara Therapeutics in a research report on Tuesday, December 3rd. Finally, ValuEngine lowered shares of Cara Therapeutics from a strong-buy rating to a buy rating in a research report on Wednesday, December 11th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of $31.14.

CARA stock opened at $16.87 on Friday. The company’s 50 day simple moving average is $16.38 and its 200-day simple moving average is $20.75. The firm has a market capitalization of $706.53 million, a PE ratio of -7.03 and a beta of 2.18. Cara Therapeutics has a 12 month low of $14.10 and a 12 month high of $27.55. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.21 and a quick ratio of 4.21.

Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The business had revenue of $5.79 million during the quarter, compared to analyst estimates of $5.56 million. Cara Therapeutics had a negative net margin of 470.70% and a negative return on equity of 70.35%. As a group, sell-side analysts anticipate that Cara Therapeutics will post -2.54 earnings per share for the current year.

In related news, Director Jeffrey L. Ives sold 2,500 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $16.13, for a total transaction of $40,325.00. Following the sale, the director now owns 8,500 shares in the company, valued at $137,105. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Frederique Ph.D. Menzaghi sold 4,000 shares of the firm’s stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $19.91, for a total transaction of $79,640.00. Following the sale, the senior vice president now owns 63,886 shares in the company, valued at approximately $1,271,970.26. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 55,934 shares of company stock worth $1,089,940. 5.80% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in CARA. Wells Fargo & Company MN boosted its position in Cara Therapeutics by 45.0% during the second quarter. Wells Fargo & Company MN now owns 158,368 shares of the biopharmaceutical company’s stock worth $3,405,000 after acquiring an additional 49,142 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Cara Therapeutics by 3.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 195,685 shares of the biopharmaceutical company’s stock worth $4,208,000 after purchasing an additional 5,717 shares during the period. Northern Trust Corp raised its stake in Cara Therapeutics by 0.4% during the second quarter. Northern Trust Corp now owns 427,656 shares of the biopharmaceutical company’s stock worth $9,194,000 after purchasing an additional 1,648 shares during the period. Parametric Portfolio Associates LLC raised its stake in Cara Therapeutics by 2.1% during the second quarter. Parametric Portfolio Associates LLC now owns 33,306 shares of the biopharmaceutical company’s stock worth $716,000 after purchasing an additional 680 shares during the period. Finally, BlackRock Inc. raised its stake in Cara Therapeutics by 3.6% during the second quarter. BlackRock Inc. now owns 2,864,551 shares of the biopharmaceutical company’s stock worth $61,587,000 after purchasing an additional 98,241 shares during the period. Hedge funds and other institutional investors own 76.08% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

Recommended Story: Bid-Ask Spread

Analyst Recommendations for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.